MolecuLight Launches the i:X® Telemedicine Solution for Imaging of Bacteria in Wounds Protection Status
Blog Category: 

By Industry News

Toronto, CANADA – July 16, 2020 – MolecuLight Inc., creator of a point-of-care fluorescence imaging device for real-time detection of bacteria in wounds, announced the launch of its new i:X® Telemedicine Solution. The i:X Telemedicine Solution provides a synchronous link between the patient's bedside and the remote wound care clinician. With this secure solution, MolecuLight i:X imaging can be performed at any care location for accurate detection of wounds containing bacteria (> 104 CFU/g) and reviewed remotely and in real-time, enabling remote clinicians to obtain objective information on the status of bacterial burden in the wound and provide guidance on patient care.

"Traditional signs and symptoms of infection in wounds can be difficult to identify remotely, and access to expert wound care professional at the bedside is increasingly limited, especially in long-term care facilities and home care clinics. The challenges of wound care in these settings have been amplified due to the restrictions in place due to COVID-19," says Anil Amlani, MolecuLight's CEO. "With the launch of our i:X Telemedicine Solution, MolecuLight offers a solution for real-time diagnostic wound imaging via telemedicine, providing additional, objective evidence to guide patient care and serving as an important link between the patient's bedside and the remote wound care clinicians."

The i:X Telemedicine Solution for wound imaging facilitates personalized patient care, and is recommended for use by MolecuLight for the following initiatives:

  • Triaging patients in home care clinics or long-term care centers to expedite intervention by wound care clinicians when concerning bacterial burden is detected in patient wounds. Such triaging also limits visits to wound care centers and hospitals for patients whose wounds are well in control,
  • Helping to monitor patients' wounds that do not have high bacterial bioburden and therefore may be able to continue remote treatment in their current setting,
  • Remotely monitor the efficacy of treatment plans over the duration of the treatment to ensure the reduction of bacterial bioburden, and
  • Remotely have the wound care professional guide the care provider at the patient bedside on how to best care for and treat the wound.

About MolecuLight Inc.
MolecuLight Inc. ( is a privately owned Canadian medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical and commercial markets. MolecuLight's initial product, the MolecuLight i:X®, and its accessories delivers a real-time handheld fluorescence imaging solution for the global wound care market. The MolecuLight i:X provides clinicians with information about the fluorescent characteristics of wounds to assist clinicians in making improved diagnostic and treatment decisions. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant, unmet needs including food safety, consumer cosmetics and other key industrial markets.

The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, Kestrel Health Information, Inc., its affiliates, or subsidiary companies.

Related company: 

Recommended for You

Important Notice: The contents of the website such as text, graphics, images, and other materials contained on the website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. The content is not intended to substitute manufacturer instructions. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or product usage. Refer to the Legal Notice for express terms of use.